NIDA Backs $6.5M Trial of Cannabis Withdrawal Medication

Anyone who has tried to stop heavy cannabis use knows the first two weeks are the hard part. Cannabis withdrawal has been treated for years as a minor inconvenience rather than a clinical problem, and that framing has left a real gap in care. There is no approved medication for it.

The National Institute on Drug Abuse is putting money toward closing that gap. NIDA awarded a $6.5 million, three-year grant to support a Phase 3 trial of an investigational treatment for cannabis withdrawal symptoms, the company developing it announced on Aug. 20.

Why Cannabis Withdrawal Matters in Detox

Withdrawal is the point where quit attempts collapse. That is true across substances, and cannabis is no exception. The symptoms named in the announcement are sleep problems, anxiety, irritability, restlessness, cravings, and physical complaints.

None of that is exotic. What makes it clinically significant is duration and timing, because the discomfort peaks precisely when a person’s motivation is being tested hardest.

More than 19 million people in the United States have cannabis use disorder, according to figures the announcement attributes to the Substance Abuse and Mental Health Services Administration.

Despite that scale, there are currently no FDA-approved pharmacologic treatments for either cannabis withdrawal syndrome or cannabis use disorder.

Compare that to opioid use disorder, which has three FDA-approved medications, or alcohol use disorder, which has several. Anyone withdrawing from cannabis today is managed with supportive care, sleep and anxiety management, and behavioral treatment rather than a targeted medication.

What the Trial Is Testing

The grant supports CAN-004, a Phase 3 trial of a compound called PP-01 in adults with moderate to severe cannabis use disorder. The first patient was dosed in June 2026, and the study is evaluating both safety and efficacy.

According to the developer, PP-01 is a once-daily oral product with a dual mechanism, targeting suppressed CB1 receptors and neurotransmitter dysregulation in the brain’s mesolimbic reward pathway.

Heavy, sustained cannabis use downregulates CB1 receptor activity, which is part of why stopping produces a withdrawal state in the first place.

Earlier-stage work has been completed. The company reports that its Phase 2b trial met its primary endpoint of reducing cannabis withdrawal symptoms, showed a dose response, and recorded no serious adverse events.

The FDA granted PP-01 Fast Track designation, a status reserved for treatments addressing serious conditions with unmet need. All of that is a reason to watch the trial, not a reason to expect a prescription. PP-01 remains investigational, Phase 3 is ongoing, and efficacy and safety conclusions wait on results.

How This Fits Withdrawal Management

Cannabis occupies an unusual position in withdrawal management, and it is worth being precise about it. Cannabis withdrawal is not physiologically dangerous the way alcohol or benzodiazepine withdrawal is.

Stopping cannabis abruptly does not carry a seizure or delirium risk. What it does carry is a high probability of returning to use, driven by symptoms that are miserable rather than life-threatening.

That distinction changes what supervised care is for. In alcohol and benzodiazepine detox, medical supervision exists partly to prevent death. In cannabis withdrawal, structured support exists to get a person through the window where relapse is most likely, and to sort out whether sleep disruption and anxiety are withdrawal effects or an underlying condition that was being self-medicated.

A medication that reliably blunted cannabis withdrawal would function much the way medication-assisted treatment does for opioid use disorder, lowering the physical cost of stopping so that behavioral treatment has time to work. That is the outcome the company describes hoping for, and it is the reason a withdrawal-specific compound is worth a Phase 3 program.

Finding Medical Detox and Withdrawal Support

If cannabis is the primary concern, the useful questions are about the surrounding care rather than the detox itself. Ask whether a program screens for co-occurring anxiety, depression, and insomnia, since those drive a large share of continued use. Ask what the plan is for the first two weeks specifically. Ask whether behavioral treatment starts immediately or after a waiting period.

If alcohol, benzodiazepines, or opioids are also involved, that changes the level of care. Medically monitored inpatient withdrawal management exists precisely for those situations, and an assessment should determine which setting fits rather than a guess.

(Sponsored)